Drug Treatment of Lipid Disorders
- 12 August 1999
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 341 (7), 498-511
- https://doi.org/10.1056/nejm199908123410707
Abstract
Arteriosclerosis of the coronary and peripheral vasculature is the leading cause of death among men and women in the United States1 and worldwide.2 In 1992, for example, cardiovascular disease accounted for 38 percent of deaths from all causes among men and 42 percent of all deaths among women in Washington State3; nationwide, the mortality rate for cardiovascular disease is approximately 50 percent.4 Mechanisms of AtherogenesisCentral to the pathogenesis of arteriosclerosis is the deposition of cholesterol in the arterial wall.5,6 Nearly all lipoproteins are involved in this process, including cholesterol carried by very-low-density lipoprotein (VLDL),7,8 remnant lipoprotein, . . .Keywords
This publication has 125 references indexed in Scilit:
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- The effects of fibrates on lipoprotein and hemostatic coronary risk factorsAtherosclerosis, 1994
- Different effects of the hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivoBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
- Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performanceClinical Cardiology, 1992
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Reduction of Serum Cholesterol in Heterozygous Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1983
- Effects of an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase on Serum Lipoproteins and Ubiquinone-10 Levels in Patients with Familial HypercholesterolemiaNew England Journal of Medicine, 1981
- Gallbladder Disease as a Side Effect of Drugs Influencing Lipid Metabolism Experience in the Coronary Drug ProjectNew England Journal of Medicine, 1977